Circulating Biomarkers and Ventricular Tachyarrhythmia
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | June 2012 |
| End Date: | October 2016 |
The purpose of this study is to determine whether levels of inflammatory markers in
circulating blood can correlate with risk for dangerous heart rhythms. Patients with
systolic heart failure, which has been shown to increase risk for dangerous heart rhythms,
will be enrolled. All subjects will have an implantable cardioverter-defibrillator (ICD) in
place, which allows regular evaluation of heart rhythm.
circulating blood can correlate with risk for dangerous heart rhythms. Patients with
systolic heart failure, which has been shown to increase risk for dangerous heart rhythms,
will be enrolled. All subjects will have an implantable cardioverter-defibrillator (ICD) in
place, which allows regular evaluation of heart rhythm.
If you agree to be in this study, you will be asked to the following things:
- you will come into the EP device clinic every three months for one year to have your
device interrogated and will complete an EKG
- you will have labs drawn to measure levels of certain markers of inflammation in the
body. This information will be used to identify new ways to test for risk of abnormal
heart rhythms and other heart disease
- you will review your medications with the study coordinator and along with any recent
illnesses or hospitalizations
- you will come into the EP device clinic every three months for one year to have your
device interrogated and will complete an EKG
- you will have labs drawn to measure levels of certain markers of inflammation in the
body. This information will be used to identify new ways to test for risk of abnormal
heart rhythms and other heart disease
- you will review your medications with the study coordinator and along with any recent
illnesses or hospitalizations
Inclusion Criteria:
- left ventricular ejection fraction [LVEF] <=35%
- ICD implant
Exclusion Criteria:
- Recent myocardial infarction (12 weeks)
- Recent revascularization (12 weeks)
- Recent hospitalization for any cause (6 weeks)
- History of rheumatologic disease
We found this trial at
1
site
New Orleans, Louisiana 70121
Principal Investigator: Daniel P Morin, MD MPH
Phone: 504-842-5059
Click here to add this to my saved trials
